Open Access Open Access  Restricted Access Subscription or Fee Access

Opioid receptor antagonists in the treatment of pathological gambling

Maurizio Coppola, MD, Raffaella Mondola, MD


no abstract

Full Text:



Fauth-Bühler M, Mann K, Potenza MN: Pathological gambling: A review of the neurobiological evidence relevant for its classification as an addictive disorder. Addict Biol. 2017; 22: 885-897.

Choi SW, Shin YC, Kim DJ, et al.: Treatment modalities for patients with gambling disorder. Ann Gen Psychiatry. 2017; 16: 23.

Kim SW, Grant JE, Adson DE, et al.: Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001; 49: 914-921.

Dannon PN, Lowengrub K, Musin E, et al.: Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: A preliminary blind-rater study. J Clin Psychopharmacol. 2005; 25: 593-596.

Dannon PN, Lowengrub K, Musin E, et al.: 12-month follow-up study of drug treatment in pathological gamblers: A primary out come study. J Clin Psychopharmacol. 2007; 27: 620-624.

Grant JE, Kim SW, Hartman BK.: A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling. J Clin Psychiatry. 2008; 69: 783-789.

Lahti T, Halme JT, Pankakoski M et al.: Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study. Psychopharmacol Bull. 2010; 43: 35-44.

Bosco D, Plastino M, Colica C, et al.: Opioid antagonists naltrexone for the treatment of pathological gambling in Parkinson’s disease. Clin Neuropsychopharmacol. 2012; 35: 118-120.

Kovanen L, Basnet S, Castrén S, et al.: A randomised, double-blind, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling. Eur Addict Res. 2016; 22: 70-79.

Grant JE, Potenza MN, Hollander E, et al.: Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006; 163: 303-312.

Grant JE, Odlaug BL, Potenza MN, et al.: Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry. 2010; 197: 330-331.

Pecina S, Smith KS, Berridge KC.: Hedonic hot spots in the brain. Neuroscientist. 2006; 12: 500-511.

Barbano MF, Cador M.: Opioid for hedonic experience and dopamine to get ready for it. Psychopharmacology. 2007;191: 497-506.

Petrovic P, Pleger B, Seymour B, et al.: Blocking central opiate function modulates hedonic impact and anterior cingulated response to reward and losses. J Neurosci. 2008; 28: 10509-10516.

Porchet RI, Boekhoudt L, Studer B, et al.: Opioidergic and dopaminergic manipulation of gambling tendencies: a preliminary study in male recreational gamblers. Front Behav Neurosci. 2016; 7: 138.

Crowley TJ, Wagner JE, Zerbe G, et al.: Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiatry. 1985; 142(9):1081–1084.

Verebey KG, Mulé SJ.: Naltrexone (Trexan): a review of hepatotoxicity issues. NIDA Res Monogr. 1986; 67: 73-81.



  • There are currently no refbacks.
This site uses cookies to maintain session information critical to the user's experience and environment on this system. Click "Accept Cookies" to continue.
For more details please visit our privacy statement at: Privacy & GDPR